T1	Participants 424 491	Verapamil has shown antimanic activity in some but not all studies.
T2	Participants 503 649	we investigated verapamil, used alone or as an adjunctive treatment, in manic patients who did not respond to an initial adequate trial of lithium
T3	Participants 696 757	Subjects were treated openly with lithium in Phase 1 (n = 45)
T4	Participants 759 906	Those who failed to respond were randomly assigned to double-blind treatment in Phase 2 with either verapamil (n = 10) or continued-lithium (n = 8)
T5	Participants 908 993	Phase 2 nonresponders (n = 10) were assigned to combined verapamil/lithium in Phase 3
